Roger Kryer

Began with promotion of Gazyva(obinutuzumab), a monoclonal antibody used in combination with chemotherapy for first line untreated follicular lymphoma patients, along with Polivy(polatuzumab) monotherapy, an antibody-drug conjugate used to treat DLBCL prior to addition and approval of Pola R-CHP. Dec 2022, the FDA approved Lunsumio (mosunetuzumab) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. Lunsumio is the first CD20xCD3 T-cell engaging bispecific antibody, a new class of cancer immunotherapy.
In April 2023, the FDA Approved Polivy R-CHP(polatuzumab) in combination with Rituxin(rituximab), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), the first FDA approved therapy in nearly 20 years for the first line treatment of diffuse large B cell lymphoma. Polivy is a first-in-class anti-CD79b antibody-drug conjugate.

June 2023, the FDA granted accelerated approval for Columvi(glofitamab), a bispecific CD20/CD3 T cell engaging monoclonal antibody for the treatment of large B-cell lymphoma.

Clinical Specialist for Skin Cancer Franchise, with primary promotion responsibility for Erivedge/Vismodegib, the first approved Oral Hedgehog Pathway Inhibitor for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery or radiation. Patients with advanced BCC mostly of the Face Head & Neck areas who would require an invasive surgery along with significant repair and reconstruction following surgery.

Responsible also in 2016-2018 for Zelboraf(vemurafenib)and Cotellic(cobimetinib) a Braf Mek inhibitor Targeted Therapy Combination for patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Customers included Dermatologists, Medical Oncologists, Mohs Surgeons, Oculoplastic surgeons, and ENT Facial Plastic Surgeons.
2015 Spark Tank Team Award-Genentech company wide
2015 & 2016 Skin Division of the Year
2016 Rep Of The Year / Sales Excellence
2018 Co-Rep Of The Year / Sales Excellence
2019 Top 10 ranking
No Performance rankings provided since 2020

Rep/Trainer-Responsible for multiple products including Ovcon 35(contraceptive), Estrace and Femring(estrogen hormone), Taclonex(topical psoriasis treatment), Doryx(antibiotic acne).

Division Manager- Responsible for hiring, field training, and strategic development goals of each territory and rep. Oversee Compliance guidelines and training. Sales Performance in 1998, 1999, 2000 as Sales Specialist lead to promotion as District Manager Midwest, moving from Mobile AL to Kansas City Division, which included Kansas Nebraska Missouri Oklahoma Colorado Iowa and Parts of Illinois Indiana Kentucky, lead a team of 18 reps originally, then down to 13 before stepping back into a clinical specialist role after 4 years as DM. Thru 17 years, Clinical Specialist, Regional Trainer, Division Manager/Midwest, and then back to field rep role. Specialties included Dermatology, OBGyn, Urology, and Psychiatry.
2013- #3 of 63 in Derm Division
2012- Ranked #4 of 73 in Derm Division
2011- Finished #2 of 80 Derm Divison
2010- #13 of 90 Derm and GI combined ranking report
2007 #7 of 125 in Womens Health Division
2005 #5 of 120 in Womens Health Division
1998, 1999, 2000 Presidents Club